Disetronic doubles US sales operations:
This article was originally published in Clinica
Swiss diabetes management company Disetronic is to double its US fields sales and service organisation, in St Paul, Minnesota, in order to allow it to expand clinical support for physicians and to begin calling on primary care, diabetes educators and internal medicine physicians. "Today more and more physicians are prescribing insulin pumps and they need clinical support to back them up," said Thomas Meyer, CEO of Burgdorf-based Disetronic. The company says it is the second largest insulin pump company in the US.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.